Explore

Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology
Trendline Trendline
Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline
Trendline Trendline
ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment
Trendline Trendline
Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors
Trendline Trendline
Biopharma Companies Leverage Augmented Intelligence to Enhance Innovation and Investment Confidence

Biopharma Companies Leverage Augmented Intelligence to Enhance Innovation and Investment Confidence

Biopharma Companies Leverage Augmented Intelligence to Enhance Innovation and Investment Confidence
Trendline Trendline
FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma

FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma

FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026